ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

The Personal Side of COVID-19: A Q&A with Elna Schiopu, MD

Kurt Ullman  |  December 14, 2020

Dr. Schiopu has experienced the COVID-19 pandemic response from both clinical and research perspectives. She recently discussed her experiences with The Rheumatologist.

Filed under:Professional Topics Tagged with:COVID-19telemedicine

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Puja Khanna, Dinesh Khanna, Gary Cutter, Jeffrey Foster, Joshua Melnick, Sara Jaafar, Stephanie Biggers, AKM Rahman, Hui-Chen Kuo, Michelle Feese and Kenneth Saag  |  December 10, 2020

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.

Filed under:ACR ConvergenceConditionsDrug UpdatesGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence – GoutACR Convergence 2020ACR Convergence 2020 – GoutGout

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

Philip Seo, MD, MHS  |  December 9, 2020

“It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. After some fits and starts, I finally struck upon a pat answer…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

Medicare’s Most Favored Nation Is My Least Favorite Notion!

Angus B. Worthing, MD  |  December 8, 2020

In case you missed it, on Nov. 20, the  Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…

Filed under:Legislation & AdvocacyOpinionProfessional TopicsSpeak Out Rheum Tagged with:MedicareMost Favored Nation

ACR Convergence graphic

10 Clinical Insights from Rheumatology Top Secrets & Pearls

Vanessa Caceres  |  December 7, 2020

In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2020DiagnosisGCAgiant cell arteritis (GCA)Inflammatory Eye DiseaseVasculitis

A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

Jason Liebowitz, MD, FACR  |  December 7, 2020

During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2020anifrolumabaxial spondyloarthritis (SpA)Clinical researchCOVID-19GlucocorticoidsLupusrituximabVasculitis

2020 Pediatric Rheumatology Research in Review

Carina Stanton  |  November 24, 2020

ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:COVID-19geneticshealth disparitiesJuvenile Arthritis (JIA)Kawasaki diseaseMultisystem Inflammatory Syndrome in Children (MIS-C)Pediatric Rheum

Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020

Elizabeth (Blair) Solow, MD  |  November 23, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered …

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RABlair SolowElizabeth SolowHCQHYDROXYCHLOROQUINEHydroxychloroquine (HCQ)

ACR Introduces Draft Guideline for RA Management

Jason Liebowitz, MD, FACR  |  November 23, 2020

Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

ACR Convergence 2020

Treatment of Lupus Nephritis Continues to See Progress

Thomas R. Collins  |  November 23, 2020

Three doctors reported on advances in research & treatments for lupus nephritis.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020Lupus nephritis

  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 72
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences